To include your compound in the COVID-19 Resource Center, submit it here.

Immunocore adds $40M from Gates Foundation

T cell receptor (TCR) company Immunocore Ltd. (Abingdon, U.K.) received a $40 million equity investment from the Bill &

Read the full 192 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE